Perceived quality of life in patients with psoriasis treated with interleukin 17 and 23 inhibitors.
In: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2024-02-28
Online
academicJournal
Zugriff:
Objective: To determine the effectiveness in terms of quality of life perceived by adult patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors and to identify associated factors.
Method: Cross-sectional observational study including adult patients diagnosed with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors for at least 12 or 16 weeks in follow-up, respectively.
Results: Forty-one patients were included: 65% male, median age 54 years (SD=13). The included patients were treated with ixekizumab 35%, guselkumab 25%, secukinumab 17.5%, brodalumab 15% and risankizumab 7.5%. Psoariasis area severity index (PASI) reduction was 94.6% (RIC 76.8-100%), DLQI of 1 (RIC 0-2.75), DLQI ≤ 1, 60%. The most affected health dimensions were symptoms and perceptions (57.5%), activities of daily living (27.5%) and discomfort caused with treatment (17.5%). No association was found between DLQI score < 1 and demographic, comorbidities and treatment-related variables. The median PASI reduction in patients with DLQI<1 was superior to patients with DLQI > 1 (100% vs 90.2%, p=0.025).
Conclusions: Patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors achieve adequate therapeutic targets achieving the target set according to clinical practice guideline recommendations (score ≤1 on the DLQI questionnaire and 90-100% reduction in the PASI index) and in accordance with the results of recent meta-analyses and real-life studies. A greater reduction of the PASI index is observed in the group reaching the quality of life target, there being the possibility of using patient-reported outcomes in the evaluation of treatment effectiveness.
(Copyright © 2024. Publicado por Elsevier España, S.L.U.)
Titel: |
Perceived quality of life in patients with psoriasis treated with interleukin 17 and 23 inhibitors.
|
---|---|
Autor/in / Beteiligte Person: | Anguita-Montenegro, B ; Areas-Del Águila, VL ; Palacios-Moya, E ; García-Arpa, M ; Sánchez-Caminero, MP ; Luque-Jiménez, M |
Link: | |
Zeitschrift: | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2024-02-28 |
Veröffentlichung: | Ahead of Print, 2024 |
Medientyp: | academicJournal |
ISSN: | 2171-8695 (electronic) |
DOI: | 10.1016/j.farma.2024.01.004 |
Sonstiges: |
|